Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

Next Previous
Trial Profile

Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium phenylbutyrate/ursodoxicoltaurine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CENTAUR
  • Sponsors Amylyx Pharmaceuticals

    • Most Recent Events

    • 22 Feb 2024 According to an Amylyx Pharmaceuticals media release, PHOENIX trial will provide additional efficacy and safety data in a larger population of people living with ALS, building on the robust and positive results observed in this CENTAUR study.
    • 04 Dec 2023 According to Amylyx media release, analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis (ALS) from this trial published in Journal of Neurology, Neurosurgery and Psychiatry.
    • 04 Dec 2023 Results presented in the Amylyx Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top